Your browser doesn't support javascript.
loading
A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang, Zhiyu; Xu, Yanjun; Hong, Wei; Gong, Lei; Chen, Kaiyan; Qin, Jing; Xie, Fajun; Wang, Feng; Tian, Xin; Meng, Xiangrui; Feng, Wenlei; Li, Lingyan; Zhang, Baihui; Kang, Xiaoyan; Fan, Yun.
Afiliação
  • Huang Z; Department of Medical Oncology, Zhejiang Cancer Hospital; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Xu Y; Department of Medical Oncology, Zhejiang Cancer Hospital; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Hong W; Department of Medical Oncology, Zhejiang Cancer Hospital; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Gong L; Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Chen K; Department of Medical Oncology, Zhejiang Cancer Hospital; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Qin J; Department of Medical Oncology, Zhejiang Cancer Hospital; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Xie F; Department of Medical Oncology, Zhejiang Cancer Hospital; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • Wang F; Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Tian X; Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Meng X; Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Feng W; Medcine Department, Qilu Pharmaceutical Co., Ltd., Jinan, China.
  • Li L; Medcine Department, Qilu Pharmaceutical Co., Ltd., Jinan, China.
  • Zhang B; Medcine Department, Qilu Pharmaceutical Co., Ltd., Jinan, China.
  • Kang X; Medcine Department, Qilu Pharmaceutical Co., Ltd., Jinan, China.
  • Fan Y; Department of Medical Oncology, Zhejiang Cancer Hospital; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Front Immunol ; 14: 1258573, 2023.
Article em En | MEDLINE | ID: mdl-37936687
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Segunda Neoplasia Primária / Miosite / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Segunda Neoplasia Primária / Miosite / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article